Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 220Lymphoid 144Other hematologic neoplasm 96Myeloid 16Genitourinary 14Dermatologic 11Gastrointestinal 9Classical hematology 6CNS 6Tumor-Agnostic 4Sarcoma 4Head & Neck 4Other solid neoplasm 3Gynecologic 3Thoracic 2Endocrine 2NET 1Breast 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Neuroendocrine Tumors 1Kidney Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Nivolumab 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lenalidomide × Endocrine × Clear all
NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Emory University

Phase 1 Completed
44 enrolled 9 charts
EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡